Zevra Therapeutics Inc. (ZVRA)
NASDAQ: ZVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 11.07 -0.09%
ZVRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $657.97M
- P/E (TTM)
- 12.04
- Forward P/E
- 10.29
- EPS (TTM)
- $0.92
- Dividend yield
- None
- 52-week range
- 8.01 – 15.04
- Day range
- 10.57 – 11.38
- Volume / Avg
- 936.12K / 1.16M
- Beta
- —
- Shares outstanding
- 59.38M
- Next earnings
- Nov 4, 2026
52-week range
ZVRA stock today
Shares of Zevra Therapeutics (ZVRA) finished higher on Oct 7 at $11.08, a gain of 3.26% or $0.35 per share, versus the S&P 500's 0.22% decline. Shares are 26.3% below their 52-week high of $15.04, set on Jul 8, 2026 and 38.3% above the 52-week low of $8.01, in the middle of the past year's range. ZVRA is up 23.7% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 8.7%.
At 12.0x trailing earnings, Zevra Therapeutics trades above the peer-group median of 5.4x. Its forward P/E of 10.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Zevra Therapeutics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Zevra Therapeutics
Company profile- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $0.14
Zevra Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FTHFaeth Therapeutics Inc. | 24.92 | -7.33% | $643.94M | vs ZVRA |
| SGMTSagimet Biosciences Inc. Series A | 8.88 | +1.37% | $629.67M | vs ZVRA |
| IRWDIronwood Pharmaceuticals Inc. Class A | 3.75 | +3.31% | $619.65M | vs ZVRA |
| ABUSArbutus Biopharma Corporation | 4.29 | -4.24% | $657.55M | vs ZVRA |
| CLYMClimb Bio Inc. | 10.71 | +0.28% | $615.14M | vs ZVRA |
| NVCTNuvectis Pharma Inc. | 20.29 | +1.30% | $662.35M | vs ZVRA |
| SLNSilence Therapeutics Plc American Depository Share | 9.82 | -0.10% | $610.35M | vs ZVRA |
| PHARPharming Group N.V. ADS | 9.65 | -0.31% | $683.01M | vs ZVRA |
Indexes, lists and sector
Largest Health Care stocks
Zevra Therapeutics stock FAQ
What is Zevra Therapeutics's stock price today?
ZVRA last traded at $11.08 as of Oct 7, 4:00 PM EDT, up 3.26% on the day. Prices are delayed at least 15 minutes.
Does Zevra Therapeutics pay a dividend?
No. Zevra Therapeutics does not currently pay a regular cash dividend.
When is Zevra Therapeutics's next earnings date?
Zevra Therapeutics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $0.14.
What is ZVRA's P/E ratio?
ZVRA trades at a trailing P/E ratio of 12.04 and a forward P/E of 10.29, compared with a median of 5.4 for its closest peers.
Has ZVRA ever split its stock?
Yes. The most recent ZVRA stock split was a 1-for-16 split on Dec 28, 2020.
What is the ZVRA 52-week high?
The 52-week high for ZVRA is $15.04 and the 52-week low is $8.01. The stock is currently 26.3% below its high.